Answer: The International Testing Agency (ITA) is authorized by the International Olympic Committee (IOC) to conduct Doping Control activities during the 2024 Paris Summer Olympic Games.

Answer: The IOC Anti-Doping Rules are in effect from the opening of the Olympic Village (July 18, 2024) until the Closing Ceremony of the Games (August 11, 2024).

Answer: The Paris 2024 Organizing Committee is responsible for the Sample Collection Authority during the Olympic Games.

Answer: The AFLD, in close collaboration with the ITA, will conduct Doping Control activities before and during the Olympic Games.

Answer: The ITA is responsible for managing the results of ADRVs on behalf of the IOC. If an ADRV is confirmed, the ITA will refer the case to the Court of Arbitration for Sport's Anti-Doping Division (CAS ADD).

Answer: The IOC is responsible for the overall management of the anti-doping program during the Games, overseeing the ITA's Doping Control activities, risk assessment, test distribution planning, Therapeutic Use Exemptions (TUEs), and results management.

Answer: The main collaborating organizations include the IOC, ITA, Paris 2024 Organizing Committee, and the French National Anti-Doping Agency (AFLD).

Answer: If an ADRV is detected, the ITA will handle the results management process, including referring the case to the CAS Anti-Doping Division. The athlete may face sanctions such as disqualification and suspension, depending on the severity of the violation.

Answer: The CAS Anti-Doping Division is responsible for resolving disputes related to ADRVs during the Games. The CAS will conduct hearings to ensure proper procedures are followed for the athletes.

Answer: The Prohibited List is a document published by the World Anti-Doping Agency (WADA) that details substances and methods prohibited in sport. The 2024 Prohibited List is available in multiple languages, including Azerbaijani, English, Arabic, French, German, and Spanish. It can be accessed from the WADA, AMADA, and ITA websites.
o amada.az
o wada-ama.org

Answer: Athletes must check all medications, including prescription and over-the-counter drugs, to ensure they do not contain prohibited substances. They should consult their team doctors and use resources like Global Drug Reference Online (Global DRO) or the AFLD platform.
o medicaments.afld.fr
o globaldro.com/CH/search
o WADA 2024 Prohibited List (ita.sport)

Answer: Dietary supplements may be contaminated with prohibited substances due to lack of strict manufacturing and labeling controls. This can result in a positive doping test and an Anti-Doping Rule Violation (ADRV). Athletes are advised not to use dietary supplements without checking the Prohibited List and consulting medical personnel.

Answer: Athletes should consult their team doctors or medical support personnel, and use the Global Drug Reference Online (Global DRO) database or the AFLD platform if in France. These resources help determine if the medications contain prohibited substances.

Answer: Athletes and their support personnel need to be aware of the key change regarding tramadol. WADA has prepared an information sheet about tramadol, which is available on the WADA website. Athletes and their support staff should review this sheet to understand the implications of the ban.

Answer: Team doctors are responsible for advising athletes on the status of medications, checking the Prohibited List, and ensuring that prescribed medications are safe and comply with anti-doping regulations.

Answer: WADA updates the Prohibited List annually, and it comes into effect on January 1st each year. Athletes need to stay informed about any changes to avoid the accidental use of substances that have been recently added to the list.

Answer: Athletes must apply for a Therapeutic Use Exemption (TUE) before using a medication that is on the Prohibited List. This allows them to use the medication for legitimate medical reasons with the necessary authorization.

Answer: Over-the-counter medications and dietary supplements may contain prohibited substances or be contaminated. Athletes must check the status of these products and exercise caution to prevent accidental doping.

Answer: A TUE is a document that allows an athlete to use a prohibited substance or method for medical reasons. This document enables athletes with medical conditions to continue competing while receiving necessary treatment.

Answer: Athletes must submit detailed medical documentation to the International TUE Committee (ITUEC) designated by the ITA. The application must include medical evidence supporting the necessity of the prohibited substance or method. More information on the TUE process for the 2024 Paris Summer Olympic Games can be found on the ITA website.
o Therapeutic Use Exemptions (TUE) (ita.sport)

Answer: Athletes with a TUE issued by their National Anti-Doping Organization or International Federation (IF) must apply to the International Paralympic Committee (IPC) for recognition. The TUE must be recorded in ADAMS and recognized by the IPC to be valid for the athlete.

Answer: From August 5, 2024, all athletes must submit a completed TUE application with medical documentation to the IPC TUE Committee via ADAMS or by email to tue@paralympic.org . The TUE will only be valid for the duration of the Games.

Answer: The most common reason for TUE denial is the lack of proper medical documentation. Athletes and their medical staff must meticulously document all medical treatments, diagnoses, and treatment plans.

Answer: The main criteria for granting a TUE include presenting detailed medical documentation showing that the prohibited substance or method is necessary for treating the medical condition, no suitable alternative treatment is available, and the substance does not significantly enhance performance.

Answer: Yes, athletes can apply for a retroactive TUE in urgent and emergency situations or when there was not enough time to apply for a TUE before treatment. The conditions for retroactive TUEs are outlined in the International Standard for Therapeutic Use Exemptions (ISTUE).
o International Standard for Therapeutic Use Exemptions (ISTUE) | World Anti Doping Agency (wada-ama.org)

Answer: The duration of a TUE depends on the medical condition and treatment. Some TUEs are valid for a specific period, while others must be reviewed and renewed regularly. Athletes should check the specific terms of their TUE.
o resource - Therapeutic Use Exemption | World Anti Doping Agency (wada-ama.org)

Answer: If a TUE application is denied, the athlete can appeal the decision to the relevant authority, such as the TUE Committee or the Court of Arbitration for Sport (CAS). They should review the reasons for denial, gather additional medical evidence, and follow the appeal procedures.

Answer: Team doctors play a crucial role in conducting medical assessments, completing necessary documentation, and supporting the athlete in submitting the TUE application. They ensure all medical information is accurate and meets the requirements of the TUE process.

Answer: Precise whereabouts information is essential for effective out-of-competition testing, ensuring athletes are available for testing at any time. This helps maintain the integrity of the anti-doping program and protects clean athletes.

Answer: The ITA Rooming List App will be used to manage athletes' whereabouts information during the Olympic Games. National Olympic Committees (NOCs) must provide rooming information for all their athletes via this app.
o https://toolkit.ita.sport/NOC

Answer: NOCs must enter the stay duration and whereabouts information for all athletes and update it if there are any changes in room assignments. This information must be provided within 24 hours after the athletes' arrival at the Olympic Village or other official venues.

Answer: National Paralympic Committees (NPCs) must provide travel schedules, room assignments, and any special accommodation details for all athletes accurately and promptly. This information must be submitted within 24 hours after the NPC’s final Registration Meeting and updated as needed.

Answer: Failure to provide accurate whereabouts information can lead to disciplinary actions for athletes and NOCs/NPCs. This may include financial penalties for NPCs not fulfilling their whereabouts information duties during the Paralympic Games.

Answer: The ITA Rooming List App is used to collect and manage rooming information for all athletes in the delegation. This helps ensure athletes can be easily located for doping control purposes.

Answer: NOCs can update whereabouts information using the ITA Rooming List App. They must enter any changes in the stay duration and location for all athletes and ensure the information is updated promptly.

Answer: If athletes fail to provide their whereabouts information, they may face disciplinary actions, including sanctions.

Answer: If athletes need to change their address, they must immediately inform their NOC or NPC. The new information should be updated in the ITA Rooming List App or the IPC reporting system to ensure the athlete’s location information is accurate and up to date.

Answer: During the Games, athletes can be asked to provide urine and blood samples at any time and any place without prior notice. This includes methods such as Dried Blood Spot (DBS) testing and gene doping tests.

Answer: In-Competition testing covers the period from 23:59 the day before the athlete's scheduled competition until the end of the competition and the completion of the related sample collection process. Out-of-Competition testing refers to any Doping Control that is not In-Competition.

Answer: On the day of the Closing Ceremony, all athletes must complete their tests before attending the ceremony. Arrangements will be made to ensure that athletes required at the ceremony can complete their tests and participate in the ceremony.

Answer: Athletes, their support personnel, or the athlete’s IOC can request a test to verify a national or regional record. The cost of the required test will be borne by the requesting party, and the procedure for requesting the test will be confirmed before the Games begin.

Answer: The International Standard for Testing and Investigations (ISTI) allows necessary modifications to the sample collection process for athletes with impairments while ensuring the integrity of the process. Athletes are responsible for providing additional equipment needed for urine sample collection. They should consult medical professionals for suitable collection devices if unsure.

Answer: Both In-Competition and Out-of-Competition tests will be conducted during the Games. This includes the collection of urine and blood samples, as well as the use of methods like Dried Blood Spot (DBS) and genetic doping tests.

Answer: Athletes who need additional personal equipment, such as catheters or drainage systems, to provide a urine sample must bring these items with them. If unsure about the appropriate equipment, they should consult with medical personnel.

Answer: If an athlete refuses to provide a urine sample, they may face an Anti-Doping Rule Violation (ADRV) for failing to comply with Doping Control regulations. Athletes should report any difficulties and cooperate with the doping control officer to provide the required sample.

Answer: The sample collection process may involve ITA staff, IPC personnel, WADA Independent Observers, and translators if needed. These individuals ensure compliance with procedures, provide support, and facilitate communication during the testing process.

Answer: The samples collected during the Games will be analyzed by the Laboratoire Anti-Dopage Français (LADF), a WADA-accredited laboratory located in Paris, at Université de Paris-Saclay.

Answer: The test analysis results for the Olympic Games are reported by the International Testing Agency (ITA) to the International Olympic Committee (IOC) and via the Anti-Doping Administration and Management System (ADAMS) managed by WADA.

Answer: The test analysis results for the Paralympic Games are reported by LADF to the International Paralympic Committee (IPC) and WADA through ADAMS.

Answer: Analysis results are reported by LADF within the notification period established by the Code. Samples requiring additional analysis may take more time.

Answer: If an Adverse Analytical Finding (AAF) is reported from the samples collected as part of the Games' doping control program, it is managed according to the IOC Anti-Doping Rules and IPC Games Rules. Appropriate procedures for results management are followed.

Answer: The WADA-accredited laboratory conducts tests to detect prohibited substances, confirm positive findings, perform gene doping tests, and analyze Dried Blood Spots (DBS) among other specialized tests.

Answer: The ITA and IPC work closely with the WADA-accredited laboratory to ensure quick collection, transportation, and analysis of samples.

Answer: If a sample requires additional analysis, such as confirmation of an Adverse Analytical Finding (AAF), the laboratory conducts further tests. This may extend the analysis time but ensures accurate and reliable results.

Answer: The confidentiality of sample analysis results is protected through secure data management systems like ADAMS. Only authorized personnel have access to the results, and strict protocols are followed to protect athletes' privacy.

Answer: The International Testing Agency (ITA) is responsible for managing the results of ADRVs under the jurisdiction of the IOC. This includes reporting and handling violations.

Answer: If an ADRV is confirmed, notifications are simultaneously sent to the athlete and the National Olympic Committee (NOC). The International Federation (IF), National Anti-Doping Organization (NADO), IOC, and WADA are also informed at the same time.

Answer: If a hearing is required for an ADRV, it will be conducted before the Court of Arbitration for Sport (CAS) according to the IOC Anti-Doping Rules and CAS Anti-Doping Division (CAS ADD) procedural rules.

Answer: The International Paralympic Committee (IPC) is responsible for managing the results of ADRVs during the Paralympic Games, in accordance with the IPC Anti-Doping Code and the International Standard for Results Management (ISRM).

Answer: Athletes found guilty of an ADRV may face various sanctions, including:
o Exclusion from sports competitions
o Banning from international competitions
o Suspension from team activities
o Disqualification of medals, awards, points, results, and achievements
o Lifetime ban from sports in some cases
o Suspension from a sports career, including coaching roles

Answer: Upon confirmation of an ADRV, the ITA simultaneously notifies the athlete, their NOC, the relevant IF, the NADO, the IOC, and WADA. This ensures that all relevant parties are informed in a timely manner.

Answer: The CAS Anti-Doping Division (CAS ADD) resolves disputes related to ADRVs during the Games. If a hearing is required, it is conducted with CAS ADD to ensure proper procedure and fair resolution.

Answer: The ITA manages the ADRV results process on behalf of the IOC. This includes conducting investigations, confirming violations, sending notifications to relevant parties, and coordinating hearings with CAS ADD. The IOC holds overall responsibility for ensuring compliance with the World Anti-Doping Code.

Answer: Participants can share information related to an ADRV via ITA's dedicated email address (Paris2024_intelligence@ita.sport ) or through ITA's confidential reporting platform REVEAL (www.reveal.sport). This information can be shared before and during the Games.

Answer: ITA's confidential reporting platform, REVEAL, is an encrypted and secure channel for sharing any doping suspicions or information. This platform allows athletes, coaches, medical personnel, and other participants to report anonymously and confidentially to help protect the integrity of the sport.

Answer: Participants can share information related to an ADRV for the Paralympic Games through WADA's Speak Up platform (https://speakup.wada-ama.org/frontpage).

Answer: ITA ensures that all information shared via ADCOM and REVEAL platforms is managed confidentially and securely. These measures are aimed at protecting clean athletes and maintaining the integrity of the sport.

Answer: Participants can request personal contact with an ITA Investigation and Research specialist through the ADCOM platform. This ensures that sensitive information is collected appropriately and securely.

Answer: If an athlete has information about a potential ADRV, they should share this information via ITA's confidential reporting platform REVEAL or the dedicated email address (Paris2024_intelligence@ita.sport ). This ensures the information is managed securely and confidentially.

Answer: The REVEAL platform uses encryption and secure data management methods to protect the identity of the informant. Informants can choose to remain anonymous while providing detailed information about suspected doping activities.

Answer: ITA uses the collected information to conduct investigations, identify patterns, and take appropriate actions against potential ADRVs. This information helps enhance the effectiveness of the anti-doping program and protect clean athletes.